Albert David Q1 FY27 Results: Revenue Rs 101 Cr, PAT Rs 31 Cr and Key Highlights

August 7, 2026
Posted by: Ankit Jaiswal
Category: News

Albert David Q1 FY27 results declared Aug 6, 2026. Revenue Rs 101 Cr (+43.60% YoY). PAT Rs 31 Cr (+303.12% YoY). CMP Rs 730.55 (+5.45%).

Albert David Q1 FY27 results were announced on August 6, 2026, on a Standalone basis. Albert David Q1 FY27 results show revenue grew +43.60% year-on-year to Rs 101 Cr from Rs 70 Cr in Q1 FY26, reflecting sustained demand in the Pharmaceuticals segment. The broader Nifty Pharma index also reflected mixed sentiment during the quarter.

Operating profit improved +164.00% YoY to Rs 8 Cr from Rs -13 Cr, indicating stronger operational efficiency. PAT surged +303.12% YoY to Rs 31.00 Cr from Rs 7.00 Cr in Q1 FY26. The quarterly numbers offer a detailed picture of how the company is navigating the current pharmaceuticals environment.

Click Here – Get Free Investment Predictions

Table of Contents

Albert David Q1 FY27 Financial Highlights

Metric	Q1 FY27 (Rs Cr)	Q1 FY26 (Rs Cr)	YoY Change
Albert David Revenue	101	70	+43.60%
Operating Profit	8	-13	+164.00%
Net Profit (PAT)	31	7.00	+303.12%
Reporting Basis	Standalone

Albert David Q1 FY27 Performance Analysis

Check the Univest Screener for Live Data on This Stock

Albert David Q1 FY27 results reflect exceptional fundamentals across key financial parameters. Revenue momentum continued on a strong footing with the top line reaching Rs 101 Cr for the April to June 2026 quarter.

Operating profit stood at Rs 8 Cr, expanding +164.00% YoY. Margin improvement signals better cost absorption and product mix optimisation.

PAT of Rs 31 Cr marks a +303.12% year-on-year improvement. Investors monitoring Albert David Q1 FY27 results will note this as a key milestone for FY27 tracking.

Key Business Factors in Albert David Q1 FY27 Results

Revenue Growth Momentum in the Pharmaceuticals Segment

Albert David Q1 FY27 results demonstrate consistent top-line expansion, with revenue rising +43.60% YoY to Rs 101 Cr. Volume-led growth and pricing discipline in key markets drove the uptick.

Operating Margin Expansion Signals Efficiency Gains

Operating profit in Albert David Q1 FY27 results rose +164.00% YoY to Rs 8 Cr. This reflects tighter cost control, better product mix, and operating leverage as the company scales volumes in core business lines.

PAT Performance and Profitability Trend

Net profit in Albert David Q1 FY27 results stood at Rs 31 Cr (+303.12% YoY). The sustained PAT growth reflects the company’s improving financial profile.

Dividend Details

No dividend was announced along with Albert David Q1 FY27 results. The company is likely retaining earnings for reinvestment into growth capex and working capital requirements.

FY27 Outlook for Albert David

Albert David is positioned to maintain growth momentum into Q2 FY27 and beyond, supported by order visibility, operational improvements, and sector tailwinds. Management guidance points toward continued expansion in the Pharmaceuticals business with a focus on margin improvement and market share consolidation. Investors tracking Albert David Q1 FY27 results are advised to consult a SEBI-registered financial advisor before making decisions.

Albert David Stock Performance After Q1 FY27 Results

Download the Univest iOS App or Univest Android App to track Albert David live price and get daily stock recommendations.

Albert David shares were trading higher at Rs 730.55 (+5.45%) on August 6, 2026, following the declaration of Albert David Q1 FY27 results. The stock reaction reflects investor sentiment on near-term earnings trajectory and sector outlook. CMP stood at Rs 730.55 on the results date, with a 52-week range reflecting the broader market sentiment toward the pharmaceuticals sector.

Key Risks for Albert David

Sector-Specific Headwinds

US FDA regulatory actions, pricing pressure in generics, and USFDA import alerts remain core risks.

Valuation and Earnings Risk

Valuation risk remains if earnings growth fails to sustain at current levels over the next two to three quarters.

Operational and Financial Risk

Working capital intensity and cash conversion cycle elongation pose risks to standalone cash flows.

Conclusion

Albert David Q1 FY27 results demonstrate exceptional financial performance with revenue at Rs 101 Cr and PAT at Rs 31 Cr on a Standalone basis. Operating leverage and disciplined cost management will be key drivers for the rest of FY27. Investors should track upcoming management commentary on growth drivers and sector developments before taking positions.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Albert David Q1 FY27 Results

When were Albert David Q1 FY27 results declared?

Ans. Albert David Q1 FY27 results were declared on August 6, 2026. The results cover the April to June 2026 quarter on a Standalone basis.

What was Albert David revenue in Q1 FY27?

Ans. Albert David Q1 FY27 results show revenue of Rs 101 Cr, +43.60% compared to Rs 70 Cr in Q1 FY26.

What was Albert David PAT in Q1 FY27?

Ans. Net profit (PAT) in Albert David Q1 FY27 results was Rs 31 Cr, +303.12% year-on-year.

Did Albert David declare a dividend in Q1 FY27?

Ans. No dividend was declared alongside Albert David Q1 FY27 results. Investors should check the official company announcements on BSE and NSE for any future dividend declarations.

What is the FY27 outlook for Albert David?

Ans. Albert David management has outlined a focus on revenue scaling and margin improvement for the remainder of FY27. Sector tailwinds and order book visibility will be key monitorables.

How did the Albert David stock react to Q1 FY27 results?

Ans. Albert David shares were trading higher at Rs 730.55 (+5.45%) on August 6, 2026, following the Albert David Q1 FY27 results announcement. Investors should consult a SEBI-registered financial advisor before acting on price movements.

News

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.